Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. VERU
stocks logo

VERU

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
0.00
-100%
-0.367
-38.89%
0.00
-100%
-0.377
-37.22%
--
--
-0.447
-10.67%
Estimates Revision
The market is revising No Change the revenue expectations for Veru Inc. (VERU) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -28.19%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-28.19%
In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Veru Inc (VERU.O) is -1.48, compared to its 5-year average forward P/E of -7.54. For a more detailed relative valuation and DCF analysis to assess Veru Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-7.54
Current PE
-1.48
Overvalued PE
15.66
Undervalued PE
-30.74

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
10.57
Current PS
0.00
Overvalued PS
21.43
Undervalued PS
-0.29
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

VERU News & Events

Events Timeline

(ET)
2025-10-30
08:25:12
Veru sets price for 1.4 million shares at $3.00 in public offering with underwriters
select
2025-10-30
08:23:01
Veru reveals pricing details for $25 million public offering
select
2025-10-29 (ET)
2025-10-29
16:05:25
Veru reveals common stock and warrant offering, amount unspecified
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
1.0
10-31Newsfilter
Veru to Showcase Two Abstracts at ObesityWeek 2025

  • Presentation at ObesityWeek 2025: Veru Inc. will present two abstracts at ObesityWeek 2025, including a poster on enobosarm's effects on body weight and fat regain after discontinuing semaglutide, and an oral presentation on enobosarm's selective fat loss properties when combined with GLP-1RA.

  • Enobosarm's Clinical Studies: The Phase 2b QUALITY clinical study showed that enobosarm, when used with semaglutide, helps preserve lean mass while promoting fat loss in older patients, leading to plans for a Phase 2b PLATEAU study to further evaluate its effects on weight and physical function in patients starting GLP-1 RA treatment.

  • Future Development Plans: The planned Phase 2b PLATEAU study aims to assess enobosarm's ability to enhance weight loss and preserve muscle mass over 72 weeks, with an interim analysis at 36 weeks to evaluate changes in body composition.

  • Forward-Looking Statements: The press release includes forward-looking statements regarding the development and regulatory pathways for enobosarm, highlighting potential risks and uncertainties that could affect the company's future results and operations.

[object Object]
Preview
9.0
09-25Benzinga
Eli Lilly Halts Bimagrumab Obesity Trial Just Weeks After Initiation

  • Eli Lilly Halts Bimagrumab Study: Eli Lilly & Co. has discontinued a mid-stage study of its experimental drug bimagrumab for obesity patients with type 2 diabetes, citing strategic business reasons, while a parallel study in non-diabetic patients continues.

  • Ongoing Competition in Obesity Treatment: The halted trial aimed to evaluate the efficacy and safety of bimagrumab and tirzepatide, amidst increasing competition in the obesity treatment market from companies like Novo Nordisk, Roche, and Regeneron.

[object Object]
Preview
9.0
08-12SeekingAlpha
Veru outlines Phase III plans for enobosarm and signals upcoming FDA clarity on lean mass preservation in obesity treatment

  • Management Focus: Veru Inc. is advancing its clinical-stage biopharmaceutical efforts on cardiometabolic and inflammatory diseases, particularly through enobosarm for weight management, which has shown promising Phase IIb results in preserving lean mass while promoting fat loss.

  • Financial Outlook and Strategy: The company reported a net loss and emphasized the need for additional capital to support ongoing drug development, while actively seeking partnerships for nondilutive funding and awaiting regulatory clarity for its upcoming Phase III trial.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Veru Inc (VERU) stock price today?

The current price of VERU is 2.42 USD — it has increased 0 % in the last trading day.

arrow icon

What is Veru Inc (VERU)'s business?

Veru Inc. is a late clinical-stage biopharmaceutical company focused on developing medicines for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its drug development program includes two late-stage novel small molecules: enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator, is being developed for two indications: Phase 2b clinical QUALITY study of enobosarm as a treatment to augment fat loss and to prevent muscle loss in sarcopenic obese or overweight elderly patients receiving a GLP-1 RA who are at-risk for developing muscle atrophy and muscle weakness, and Phase 3 ENABLAR-2 clinical trial of enobosarm and abemaciclib for the treatment of androgen receptor positive, estrogen receptor positive and human epidermal growth factor receptor 2 negative metastatic breast cancer in the 2nd line setting. Sabizabulin, a microtubule disruptor, is being developed for treatment of hospitalized patients with viral-induced ARDS.

arrow icon

What is the price predicton of VERU Stock?

Wall Street analysts forecast VERU stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for VERU is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Veru Inc (VERU)'s revenue for the last quarter?

Veru Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Veru Inc (VERU)'s earnings per share (EPS) for the last quarter?

Veru Inc. EPS for the last quarter amounts to -5.00 USD, increased 566.67 % YoY.

arrow icon

What changes have occurred in the market's expectations for Veru Inc (VERU)'s fundamentals?

The market is revising No Change the revenue expectations for Veru Inc. (VERU) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -28.19%.
arrow icon

How many employees does Veru Inc (VERU). have?

Veru Inc (VERU) has 210 emplpoyees as of December 05 2025.

arrow icon

What is Veru Inc (VERU) market cap?

Today VERU has the market capitalization of 38.84M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free